Therapeutic effect evaluation of Fu-Zheng Jie-Du Xiao-Ji approach in the treatment of hepatitis B virus-related hepatocellular carcinoma

Phase 1

Completed

• Conditions: iver cancer

• Registration Number: ITMCTR2000003404
• Lead Sponsor: Beijing Ditan Hospital, Capital Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) the primary liver cancer diagnosis standard;
(2) Chronic hepatitis B virus infection;
(3) Male or female aged 18-65 years;
(4) Deficiency of qi and Yin and accumulation of poison and blood stasis;
(5) Sign the informed consent.

Exclusion Criteria

(1) Liver cancer patients with metastasis from other tumors;
(2) Patients with other malignant tumors;
(3) Patients with serious heart and kidney complications or other primary diseases; Psychopaths;
(4) Upper gastrointestinal bleeding;
(5) Hepatorenal syndrome;
(6) Pregnant or lactating women;
(7) Patients cannot cooperate.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
TCM syndrome score;Child-Pugh class;Medium survival time;Liver function;AFP level;Overall survival of 48 weeks;Remission rate of solid tumors;Complication rate;